Igor Odintsov

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Romel Somwar, Nicolle E. Hofmann, Bryan D. Smith et al. · Communications Biology · 2020 · 60 citations · Full text

Acquired <i>MET</i> Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in <i>EGFR</i> -Mutated Lung Cancer

Ken Suzawa, Michael Offin, Adam J. Schoenfeld et al. · JCO Precision Oncology · 2019 · 54 citations · Full text

Tumor Biology, Oncology, Met Amplification +15

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> Fusions

Igor Odintsov, Allan J.W. Lui, Whitney J. Sisso et al. · Clinical Cancer Research · 2021 · 48 citations · Full text

Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor

Koichi Ogura, Romel Somwar, Julija Hmeljak et al. · Clinical Cancer Research · 2020 · 30 citations · Full text

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

Igor Odintsov, Marissa S. Mattar, Allan J.W. Lui et al. · Journal of Thoracic Oncology · 2021 · 30 citations · Full text

Medicine, Therapeutic Strategies, Mtor Signaling +9